Epitalon attracts longevity and sleep interest because it is often framed around aging biology and circadian function.
FDA found limited clinical information and unresolved product-characterization questions for the reviewed insomnia use.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
3 names in this peptide family.
Epitalon and Epithalon are resolved as aliases; acetate and free-base references remain visible.
4 evidence questions.
Human benefitLimited human evidenceDoes Epitalon have established human clinical benefit for insomnia?
FDA approvalNo FDA approval identifiedIs Epitalon FDA approved?
503A statusRegulatory recordIs Epitalon on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled Epitalon automatically interchangeable?
See every Epitalon evidence question →Open the machine-readable record ↗PCAC gave a favorable advisory recommendation
The committee recommended Epitalon-related bulk drug substances for possible inclusion on the 503A Bulks List.
FDA received advice from its expert compounding committee.
The compound was not FDA-approved, and the vote alone did not add it to the final 503A Bulks List.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
PCAC gave a favorable advisory recommendation
The committee recommended Epitalon-related bulk drug substances for possible inclusion on the 503A Bulks List.
Read the source ↗FDA published its scientific briefing
FDA released its evaluation of Epitalon-related bulk drug substances for the committee meeting.
Read the source ↗Epitalon entered FDA's 503A nomination record
Two organizations nominated epitalon-related substances. The nominations were later withdrawn, and FDA continued the evaluation on its own initiative.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
FDA found limited clinical information and unresolved product-characterization questions.
Read the FDA review ↗Preclinical findings were reviewed separately and do not establish clinical benefit in people.
Read the FDA review ↗Epitalon increased telomere length in cultured normal and cancer cell lines. A cell-culture result does not establish longevity, sleep, or other clinical benefit in people.
Read the study on PubMed ↗Important unknowns.
- Human safety information is limited for the proposed routes and uses.
- FDA identified uncertainty around active-ingredient characterization, peptide-related impurities, or aggregation.
- Limited evidence of harm should not be interpreted as evidence of safety.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
3 dated changes. 3 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.